摘要:
The present invention relates to compounds which are of use in the field of agriculture as fungicides. The compounds are derivatives of succinate dehydrogenase inhibitors (SDHIs) which comprise different linker groups in place of the SDHI central amide. The invention also relates to uses, methods of use and compositions comprising said SDHI derivatives.
摘要:
Disclosed herein is a highly enantio- (75 to 98%ee)and diastereoselective (99 to 100%de)synthesis of functionalised pyrazolidines via tandem a-amination-Corey Chaykovsky reaction of alpha unsubstituted aldehydes.
摘要:
The invention is directed to novel cathepsin C inhibitors and their use in the treatment of diseases mediated by the cathepsin C enzyme. Specifically, the invention is directed to compounds according to Formula (I): wherein X and n are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are cathepsin C inhibitors and can be used in the treatment of diseases mediated by the cathepsin C enzyme, such as COPD. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting cathepsin C and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.
摘要:
Novel compounds useful for inhibiting spermatogenesis and cancer treatment, and in particular as inhibitors of heat shock proteins and/or elongation factor 1 alpha.
摘要:
Azapeptide acids of Formula (I) are antagonists of VLA-4 and/or alpha 4 beta 7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of asthma, allergies, inflammation, multiple sclerosis, and other inflammatory and autoimmune disorders.
摘要:
Aminoguanidine and alkoxyguanidine compounds, including compounds of formula (I) wherein X is O or NR?9 and R1-R4, R6-R9, R11, R12, Ra, Rb, Rc¿, Y, Z, n and m are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin are described. Also described are methods for preparing the compounds of Formula (I). The novel compounds of the present invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin, or are intermediates useful for forming compounds having antithrombotic activity. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents.
摘要:
Provided herein are compounds, compositions, and methods for treating disorders (e.g., opioid addiction) using compounds disclosed herein, which are selective agonists of the cannabinoid 2 receptor (CB2R).
摘要:
Described herein are methods and compositions for treating a spinal injury. Aspects of the invention relate to administering to a subject an agent that upmodulates KCC2. Another aspect of the invention relates to administering to a subject an agent that that reduces excitability of inhibitory interneurons. Compositions comprising these agents are additionally described herein.
摘要:
Provided are peptides comprising at least one azaamino acid and having beta-sheet breaking ability, useful in the treatment and prevention of diseases such as alzheimer's disease, Dementia Pugilistica (including head trauma), Hereditary Cerebral Haemorrhage with amyloidosis of the Dutch type (HCHWA-D) and Vascular Dementia with amyloid angiopathy.